[논문]알츠하이머성 치매에서 혈액 진단을 위한 바이오마커

박창은

doi:10.15324/kjcls.2022.54.4.249

알츠하이머성 치매에서 혈액 진단을 위한 바이오마커
Blood Biomarkers for Alzheimer's Dementia Diagnosis 원문보기

Korean journal of clinical laboratory science : KJCLS = 대한임상검사과학회지, v.54 no.4, 2022년, pp.249 - 255

초록
AI-Helper

알츠하이머병은 주요한 공중보건 문제로 나타나며 연구분야에서도 최우선적인 과제이다. 알츠하이머병(AD)에서 뇌척수액(CSF)을 활용한 바이오마커인 아밀로이드-β(Aβ42), 총 타우(T-tau) 및 인산화 타우(P-tau)가 알츠하이머병 병태생리학의 핵심 요소를 반영한다. 임상 연구 및 새로운 측정법을 통한 임상적으로 활용되는 진단은 전임상 알츠하이머병에 대해 민감적이고 특이적이며 신뢰할 수 있는 바이오마커의 발굴, 뿐만 아니라 치매의 조기 발견 및 감별 진단과 질병 진행 모니터링에 도움이 되는 검사법의 개발에도 중요할 것이다. 증상 전 단계에서 AD의 조기 발견은 시냅스 손상 및 신경 손실이 확장되기 전에 개입이 수행되기 때문에 치료 개입을 조기에 가능하게 하고 치료 성공을 위한 가능성이 더 큰 좋은 기회로 이어진다. 따라서 새롭고 접근하기 쉽고 비용이 적게 드는 바이오마커를 임상 진단에 활용하는 것이 매우 유익할 것이다. 치매의 초기단계에 일어나는 병리학적 변화나, 질병의 진행정도를 추적할 수 있는 다양한 바이오마커들의 진단방법을 찾는 일은 치료제 개발처럼 중요한 연구 분야이다. 조기진단을 위해 임상증상을 대변하거나(surrogate marker), 증상이 나타나기 이전 상태를 측정할 수 있는 새로운 진단마커가 필요한 상황이다. 이러한 이유로 인지기능 저하정도를 측정하여 정상, 경도인지장애(mild cognition impairment, MCI) 및 전임상(preclinical) 상태의 사람을 판별할 수 있는 바이오마커(biomarker)를 활용한 조기진단법 개발의 중요성이 강조되고 있다.

Abstract ▼ AI-Helper

Alzheimer's disease (AD) represents a major public health concern and has been identified as a research priority. Clinical research evidence supports that the core cerebrospinal fluid (CSF) biomarkers for AD, including amyloid-β (Aβ42), total tau (T-tau), and phosphorylated tau (P-tau), reflect key elements of AD pathophysiology. Nevertheless, advances in the clinical identification of new indicators will be critical not only for the discovery of sensitive, specific, and reliable biomarkers of preclinical AD pathology, but also for the development of tests that facilitate the early detection and differential diagnosis of dementia and disease progression monitoring. The early detection of AD in its presymptomatic stages would represent a great opportunity for earlier therapeutic intervention. The chance of successful treatment would be increased since interventions would be performed before extensive synaptic damage and neuronal loss would have occurred. In this study, the importance of developing an early diagnostic method using cognitive decline biomarkers that can discriminate between normal, mild cognitive impairment (MCI), and AD preclinical stages has been emphasized.

주제어

표/그림 (1)

표 Table 1. The list and interpretation of factors that can be used as biomarkers in the progression of Alzheimer's disease and MCI

참고문헌 (50)

Luu L, Ciccotosto GD, Cappai R. The Alzheimer's disease？amyloid precursor protein and its neuritogenic actions. Curr？Alzheimer Res. 2021;18:772-786. https://doi.org/10.2174/156720501866621120814101
Hansson O, Mikulskis A, Fagan AM, Teunissen C, Zetterberg H,？Vanderstichele H, et al. The impact of preanalytical variables on？measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: a review. Alzheimers Dement. 2018;14:1313-1333.？https://doi.org/10.1016/j.jalz.2018.05.008

상세보기
Wegmann S, Biernat J, Mandelkow E. A current view on Tau protein phosphorylation in Alzheimer's disease. Curr Opin Neurobiol.？2021;69:131-138. https://doi.org/10.1016/j.conb.2021.03.003

상세보기
Babapour Mofrad R, Scheltens P, Kim S, Kang S, Youn YC, An？SSA, et al. Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status. Alzheimers Res Ther. 2021;13:133.？https://doi.org/10.1186/s13195-021-00873-w

상세보기
Choi Y, Joh Y, Ryu JS, Kim K, Seo D, Kim S. Endogenous Aβ peptide promote Aβ oligomerization tendency of spiked synthetic？Aβ in Alzheimer's disease plasma. Mol Cell Neurosci. 2021;111:？103588. https://doi.org/10.1016/j.mcn.2021.103588

상세보기
Pyun JM, Ryu JS, Lee R, Shim KH, Youn YC, Ryoo N, et al. Plasma？amyloid-β oligomerization tendency predicts amyloid PET positivity.？Clin Interv Aging. 2021 Apr 30;16:749-755. https://doi.org/10.2147/CIA.S312473

상세보기
Konietzko U. AICD nuclear signaling and its possible contribution？to Alzheimer's disease. Curr Alzheimer Res. 2012;9:200-216.？https://doi.org/10.2174/156720512799361673
Irwin DJ, Lee VM, Trojanowski JQ. Parkinson's disease dementia:？convergence of α-synuclein, tau and amyloid-β pathologies. Nat？Rev Neurosci. 2013;14:626-436. https://doi.org/10.1038/nrn3549

상세보기
Youn YC, Lee BS, Kim GJ, Ryu JS, Lim K, Lee R, et al. Blood amyloid-β oligomerization as a biomarker of Alzheimer's disease: a？blinded validation study. J Alzheimers Dis. 2020;75:493-499.？https://doi.org/10.3233/JAD-200061

상세보기
Meng X, Li T, Wang X, Lv X, Sun Z, Zhang J, et al. Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer's disease. Alzheimers Res Ther.？2019;11:89. https://doi.org/10.1186/s13195-019-0535-7

상세보기
An SSA, Lee BS, Yu JS, Lim K, Kim GJ, Lee R, et al. Dynamic？changes of oligomeric amyloid β levels in plasma induced by？spiked synthetic Aβ42. Alzheimers Res Ther. 2017;9:86. https://doi.org/10.1186/s13195-017-0310-6

상세보기
Ivanov SM, Atanasova M, Dimitrov I, Doytchinova IA. Cellular？polyamines condense hyperphosphorylated Tau, triggering Alzheimer's disease. Sci Rep. 2020;10:10098. https://doi.org/10.1038/s41598-020-67119-x

상세보기
Lan G, Cai Y, Li A, Liu Z, Ma S, Guo T, et al. Association of presynaptic loss with Alzheimer's disease and cognitive decline. Ann？Neurol. 2022;92:1001-1015. https://doi.org/10.1002/ana.2649

상세보기
Williams SM, Schulz P, Sierks MR. Oligomeric alpha-synuclein？and beta-amyloid variants as potential biomarkers for Parkinson's？and Alzheimer's diseases. Eur J Neurosci. 2016;43:3-16. https://doi.org/10.1111/ejn.13056

상세보기
Meneses A, Koga S, O'Leary J, Dickson DW, Bu G, Zhao N.？TDP-43 Pathology in Alzheimer's disease. Mol Neurodegener.？2021;16:84. https://doi.org/10.1186/s13024-021-00503-x

상세보기
Zheng Y, Zhang L, Zhao J, Li L, Wang M, Gao P, et al. Advances in？aptamers against Aβ and applications in Aβ detection and regulation for Alzheimer's disease. Theranostics. 2022;12:2095-2114.？https://doi.org/10.7150/thno.69465

상세보기
Hugo J, Ganguli M. Dementia and cognitive impairment: epidemiology, diagnosis, and treatment. Clin Geriatr Med. 2014;30:？421-442. https://doi.org/10.1016/j.cger.2014.04.001

상세보기
Harris LD, Jasem S, Licchesi JDF. The ubiquitin system in？Alzheimer's disease. Adv Exp Med Biol. 2020;1233:195-221.？https://doi.org/10.1007/978-3-030-38266-7_8
Ruan Z, Pathak D, Venkatesan Kalavai S, Yoshii-Kitahara A,？Muraoka S, Bhatt N, et al. Alzheimer's disease brain-derived extracellular vesicles spread tau pathology in interneurons. Brain.？2021;144:288-309. https://doi.org/10.1093/brain/awaa376

상세보기
Hu S, Tan J, Qin L, Lv L, Yan W, Zhang H, et al. Molecular chaperones and Parkinson's disease. Neurobiol Dis. 2021;160:105527.？https://doi.org/10.1016/j.nbd.2021.105527

상세보기
Varesi A, Pierella E, Romeo M, Piccini GB, Alfano C, Bjorklund G,？et al. The potential role of gut microbiota in Alzheimer's disease:？from diagnosis to treatment. Nutrients. 2022;14:668. https://doi.org/10.3390/nu14030668

상세보기
Jiang C, Li G, Huang P, Liu Z, Zhao B. The gut microbiota and？Alzheimer's disease. J Alzheimers Dis. 2017;58:1-15. https://doi.org/10.3233/JAD-161141

상세보기
Chong JR, Ashton NJ, Karikari TK, Tanaka T, Scholl M, Zetterberg H,？et al. Blood-based high sensitivity measurements of beta-amyloid？and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances. J Neurol Neurosurg Psychiatry.？2021;92:1231-1241. https://doi.org/10.1136/jnnp-2021-327370

상세보기
Leuzy A, Cullen NC, Mattsson-Carlgren N, Hansson O. Current？advances in plasma and cerebrospinal fluid biomarkers in？Alzheimer's disease. Curr Opin Neurol. 2021 ;34:266-274.？https://doi.org/10.1097/WCO.0000000000000904

상세보기
Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P.？Advantages and disadvantages of the use of the CSF amyloid β (Aβ)？42/40 ratio in the diagnosis of Alzheimer's disease. Alzheimers Res？Ther. 2019;11:34. https://doi.org/10.1186/s13195-019-0485-0

상세보기
Cervellati C, Trentini A, Rosta V, Passaro A, Bosi C, Sanz JM, et al.？Serum beta-secretase 1 (BACE1) activity as candidate biomarker？for late-onset Alzheimer's disease. Geroscience. 2020;42:159-167.？https://doi.org/10.1007/s11357-019-00127-6

상세보기
Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al.？Serum neurofilament dynamics predicts neurodegeneration and？clinical progression in presymptomatic Alzheimer's disease. Nat？Med. 2019;25:277-283. https://doi.org/10.1038/s41591-018-0304-3

상세보기
Mavroudis I, Chowdhury R, Petridis F, Karantali E,？Chatzikonstantinou S, Balmus IM, et al. YKL-40 as a potential biomarker for the differential diagnosis of Alzheimer's disease.？Medicina (Kaunas). 2021;58:60. https://doi.org/10.3390/medicina58010060

상세보기
Kowalski K, Mulak A. Brain-gut-microbiota axis in Alzheimer's？disease. J Neurogastroenterol Motil. 2019;25:48-60. https://doi.org/10.5056/jnm18087

상세보기
Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Lantero？Rodriguez J, Snellman A, et al. Longitudinal associations of blood？phosphorylated tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease. JAMA Neurol. 2021;78:396-406. https://doi.org/10.1001/jamaneurol.2020.4986

상세보기
Rojas JC, Karydas A, Bang J, Tsai RM, Blennow K, Liman V, et al.？Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol. 2016;3:？216-225. https://doi.org/10.1002/acn3.290

상세보기
Katayama T, Sawada J, Takahashi K, Yahara O, Hasebe N.？Meta-analysis of cerebrospinal fluid neuron-specific enolase levels in Alzheimer's disease, Parkinson's disease, dementia with？Lewy bodies, and multiple system atrophy. Alzheimers Res Ther.？2021;13:163. https://doi.org/10.1186/s13195-021-00907-3

상세보기
Tarawneh R, D'Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, et？al. Visinin-like protein-1: diagnostic and prognostic biomarker？in Alzheimer disease. Ann Neurol. 2011 Aug;70(2):274-85.？https://doi.org/10.1002/ana.2244

상세보기
Sturchio A, Dwivedi AK, Malm T, Wood MJA, Cilia R, Sharma JS,？et al. High soluble amyloid-β42 predicts normal cognition in？amyloid-positive individuals with Alzheimer's disease-causing？mutations. J Alzheimers Dis. 2022;90:333-348. https://doi.org/10.3233/JAD-220808

상세보기
Mizoi M, Yoshida M, Saiki R, Waragai M, Uemura K, Akatsu H,？et al. Distinction between mild cognitive impairment and？Alzheimer's disease by CSF amyloid β40 and β42, and protein-conjugated acrolein. Clin Chim Acta. 2014;430:150-155.？https://doi.org/10.1016/j.cca.2014.01.007

상세보기
Mulugeta E, Londos E, Ballard C, Alves G, Zetterberg H, Blennow？K, et al. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies. J Neurol Neurosurg Psychiatry.？2011;82:160-164. https://doi.org/10.1136/jnnp.2009.199398

상세보기
Xu Y, Shen YY, Zhang XP, Gui L, Cai M, Peng GP, et al.？Diagnostic potential of urinary monocyte chemoattractant protein-1 for Alzheimer's disease and amnestic mild cognitive？impairment. Eur J Neurol. 2020;27:1429-1435. https://doi.org/10.1111/ene.14254

상세보기
Oeckl P, Halbgebauer S, Anderl-Straub S, Steinacker P, Huss AM,？Neugebauer H, et al. Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive？impairment. J Alzheimers Dis. 2019;67:481-488. https://doi.org/10.3233/JAD-180325

상세보기
Wang X, Zhang S, Lin F, Chu W, Yue S. Elevated galectin-3 levels？in the serum of patients with Alzheimer's disease. Am J Alzheimers？Dis Other Demen. 2015;30:729-732. https://doi.org/10.1177/1533317513495107

상세보기
Wang MJ, Yi S, Han JY, Park SY, Jang JW, Chun IK, et al.？Oligomeric forms of amyloid-β protein in plasma as a potential？blood-based biomarker for Alzheimer's disease. Alzheimers Res Ther. 2017;9:98. https://doi.org/10.1186/s13195-017-0324-0

상세보기
Guo Y, Hu Z, Wang Z. Corrigendum: recent advances in the application peptide and peptoid in diagnosis biomarkers of？Alzheimer's disease in blood. Front Mol Neurosci. 2022;15:865110. https://doi.org/10.3389/fnmol.2022.865110

상세보기
Shi Y, Bao Q, Chen W, Wang L, Peng D, Liu J, et al. Potential roles？of extracellular vesicles as diagnosis biomarkers and therapeutic？approaches for cognitive impairment in Alzheimer's disease. J？Alzheimers Dis. 2022;87:1-15. https://doi.org/10.3233/JAD-215666

상세보기
Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke？M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's？disease: a systematic review and meta-analysis. Lancet Neurol.？2016;15:673-684. https://doi.org/10.1016/S1474-4422(16)00070-3

상세보기
Jia L, Zhu M, Kong C, Pang Y, Zhang H, Qiu Q, et al. Blood neuro-exosomal synaptic proteins predict Alzheimer's disease at？the asymptomatic stage. Alzheimers Dement. 2021;17:49-60.？https://doi.org/10.1002/alz.12166

상세보기
Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic？approaches. Lancet Neurol. 2021;20:68-80. https://doi.org/10.1016/S1474-4422(20)30412-9

상세보기
Jung AN, Lee YJ, Choi SK, Park JO, Woo MS, Yu KN. A study on？the statistical evaluation of apolipoprotein E genotype and？Alzheimer's disease. Korean J Clin Lab Sci. 2004;36:110-114.
Jiang C, Li G, Huang P, Liu Z, Zhao B. The gut microbiota and？Alzheimer's disease. J Alzheimers Dis. 2017;58:1-15. https://doi.org/10.3233/JAD-161141

상세보기
Leuzy A, Mattsson-Carlgren N, Palmqvist S, Janelidze S, Dage JL,？Hansson O. Blood-based biomarkers for Alzheimer's disease.？EMBO Mol Med. 2022;14:e14408. https://doi.org/10.15252/emmm.202114408

상세보기
Zetterberg H, Burnham SC. Blood-based molecular biomarkers？for Alzheimer's disease. Mol Brain. 2019;12:26. https://doi.org/10.1186/s13041-019-0448-1

상세보기
Sharma L, Sharma A, Kumar D, Asthana MK, Lalhlenmawia H,？Kumar A, et al. Promising protein biomarkers in the early diagnosis of Alzheimer's disease. Metab Brain Dis. 2022;37:1727-1744.？https://doi.org/10.1007/s11011-021-00847-9

상세보기

저자의 다른 논문 :

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증